RxDoctor Payments Data

Thomas Patton, MD

Neurology · Tuscaloosa, ALNPI 1790832582

Payments from drug & device makers

$20,308in general payments, 2019–2025

Across 1,137 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Pfizer$1K
  • Biogen$1K
  • CSL Behring$1K
  • Novartis$991
  • Amgen$794
  • plus $12K from 54 others

What the payments were for

  • Speaking & faculty fees$150%
  • Food & beverage$20,293100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)199$2,755
Pfizer93$1,193
Biogen70$1,091
CSL Behring31$1,070
Novartis57$991
Amgen(2 entities)43$794
Neurocrine Biosciences, Inc.34$692
UCB, Inc.26$561
Genentech USA, Inc.26$551
Teva Pharmaceuticals USA, Inc.52$515
Eisai Inc.21$512
AstraZeneca(2 entities)23$488
Lilly USA, LLC29$437
Acadia Pharmaceuticals Inc24$422
SK Life Science, Inc.20$422
Neurelis, Inc.28$419
Argenx US, Inc.17$407
Grifols USA, LLC19$376
EMD Serono, Inc.15$355
Catalyst Pharmaceuticals, Inc.16$343
Lundbeck LLC16$343
Merz Pharmaceuticals, LLC14$319
Upsher-smith Laboratories LLC16$316
Kyowa Kirin, Inc.16$311
Ipsen Biopharmaceuticals, Inc15$300
Otsuka America Pharmaceutical, Inc.13$278
Biohaven Pharmaceutical Holding Company Ltd.11$269
Sanofi12$240
ANI Pharmaceuticals, Inc.2$237
Takeda Pharmaceuticals U.S.A., Inc.11$218
Johnson & Johnson(2 entities)12$213
Bristol Myers Squibb12$209
Adamas Pharmaceuticals, Inc.10$197
Tanabe Pharma America, Inc.10$186
TG Therapeutics, Inc.9$175
Supernus Pharmaceuticals, Inc.7$169
Amneal Pharmaceuticals LLC10$168
Biohaven Pharmaceuticals, Inc.8$152
Acorda Therapeutics, Inc8$151
Avanir Pharmaceuticals, Inc.9$136
Akcea Therapeutics, Inc.8$133
Greenwich Biosciences, Inc.7$129
MDD US Operations, LLC7$115
Jazz Pharmaceuticals Inc.6$110
Averitas Pharma Inc.3$66
Impel Pharmaceuticals Inc.3$62
Harmony Biosciences LLC3$57
Aucta Pharmaceuticals, Inc.3$57
Aquestive Therapeutics, Inc.3$56
Inspire Medical Systems, Inc.2$56
Mallinckrodt Hospital Products Inc.2$46
GE HealthCare2$42
Xeris Pharmaceuticals, Inc.2$41
Zyla Life Sciences, Inc.2$34
Avion Pharmaceuticals2$31
Assertio Therapeutics, Inc.2$30
Amylyx Pharmaceuticals, Inc.2$28
Livanova USA, Inc.1$26
Vanda Pharmaceuticals Inc.1$20
Kedrion Biopharma, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,308 in reported general payments places this provider in the 70th percentile of 255 neurology providers in Alabama.

See all neurology providers in Alabama

Medicare billing

Part B allowed, 2024
$189,905
Medicare patients
560
Services billed
9,303

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PanzygaImmun Glob G(Igg)-Ifas/Glycine26$590,360
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5026$550,724
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5026$392,444
Radicava OrsEdaravone24$356,168
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$260,246
Gamunex-CImmune Globul G/Gly/Iga Avg 4619$228,417
AustedoDeutetrabenazine24$161,333
NortheraDroxidopa13$139,693
Nurtec OdtRimegepant Sulfate54$97,530
IngrezzaValbenazine Tosylate12$87,850
UbrelvyUbrogepant60$62,030
InbrijaLevodopa13$51,660
Droxidopa17$46,495
QuliptaAtogepant23$34,042
Aimovig AutoinjectorErenumab-Aooe35$30,449

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPanzyga, Nurtec Odt$1,193$687,89080 claims
CSL BehringPrivigen$1,070$392,44426 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid, Trintellix$218$265,82125 claims
Grifols USA, LLCGamunex-C$376$228,41719 claims
Teva Pharmaceuticals USA, Inc.Austedo$515$161,33324 claims
Lundbeck LLCNorthera$343$139,69313 claims
AbbVieUbrelvy, Qulipta, Botox$2,755$125,946104 claims
Neurocrine Biosciences, Inc.Ingrezza$692$87,85012 claims
Acorda Therapeutics, IncInbrija$151$51,66013 claims
Otsuka America Pharmaceutical, Inc.Rexulti$278$21,48915 claims
Eisai Inc.Fycompa$512$19,97711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 neurology providers in Alabama.

Other neurology in Tuscaloosa

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →